Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 18 and 99 years of age
- People who have been diagnosed with epilepsy, or where epilepsy is suspected
- People who have been admitted to an Epilepsy Monitoring Unit (EMU) for investigation of their episodes, or who are receiving care at the University of Iowa Health Care Epilepsy Clinic
Who may not be able to join:
- People who have a history of heart, lung, or liver disease that is not well controlled
- People who have a progressive or uncontrolled neurological condition that is not related to epilepsy
- People who are currently using opioid medications
- Women who could become pregnant and are either currently pregnant, or have been sexually active in the past 21 days without using a highly effective form of contraception, or have a positive pregnancy test
- People who have another health condition that could affect the safety or practicality of the breathing test used in this trial (confirm with trial site)
- People who are not able to make decisions for themselves and do not have a qualified representative who can act on their behalf
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Brian Gehlbach, MD, University of Iowa
Phone: 319-356-4337
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the correlation between baseline central CO2 chemosensitivity and the increase in transcutaneous CO2 levels after a seizure.; Determine the correlation between baseline central CO2 chemosensitivity and the duration of transcutaneous CO2 elevation above baseline after a seizure.; Effect of seizures on HCVR slope (liters/min/mm Hg); Determine the stability of the HCVR slope over time in patients with epilepsy. of the HCVR over time in patients with epilepsy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.